OKYO Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 1/6

OKYO Pharma şirketinin toplam hissedar öz sermayesi $-5.9M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $1.5M ve $7.4M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$826.85k
Eşitlik	-US$5.88m
Toplam yükümlülükler	US$7.42m
Toplam varlıklar	US$1.54m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: OKYO negatif hissedar özkaynağı var; bu, kısa vadeli varlıkların kısa vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Uzun Vadeli Yükümlülükler: OKYO şirketinin negatif özkaynağı bulunmaktadır; bu, kısa vadeli varlıkların uzun vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: OKYO borçsuzdur.

Borcun Azaltılması: OKYO 'in negatif özkaynağı var, dolayısıyla borcunun zaman içinde azalıp azalmadığını kontrol etmemize gerek yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: OKYO şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: OKYO un, serbest nakit akışı her yıl % 35.4 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

OKYO Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 1/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

OKYO Pharma Limited announced delayed 20-F filing

OKYO Pharma Limited announced delayed 20-F filing

OKYO Pharma's Ordinary Shares of No Par Value, Fully Paid Cancels from Admission to Trading on London Stock Exchange

OKYO Pharma Announces Change of Delisting Date to 22 May 2023

OKYO Pharma Limited announced delayed 20-F filing

Recent updates

OKYO Pharma Limited Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

OKYO Pharma Limited Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain

OKYO Pharma Limited announced delayed 20-F filing

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

Okyo Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

OKYO Pharma Limited Announces Appointment of Scientific Advisory Board

OKYO Pharma Limited Reports Positive Safety and Efficacy Results in Its Phase 2, Randomized, Double-Masted, Placebo-Controlled Trial Evaluating the Safety and Efficacy of OK-101 Ophthalmic Solution in Patients with Dry Eye Disease

OKYO Pharma Limited has filed a Follow-on Equity Offering in the amount of $4 million.

Okyo Pharma Limited Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit

OKYO Pharma Limited, Annual General Meeting, Dec 14, 2023

OKYO Pharma Limited has completed a Follow-on Equity Offering in the amount of $1.6389 million.

Okyo Pharma Limited Announces Filing of an Investigational New Drug (Ind) Application for Ok-101 to Treat Neuropathic Corneal Pain

OKYO Pharma Limited Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease (DED)

OKYO Pharma Limited has completed a Follow-on Equity Offering in the amount of $4.000005 million.

OKYO Pharma Limited has completed a Follow-on Equity Offering in the amount of $4.000005 million.

Okyo Pharma Limited Completes Enrollment in Phase 2 Clinical Trial of Ok-101 to Treat Dry Eye Disease

OKYO Pharma Limited announced delayed 20-F filing

OKYO Pharma Limited Plans to Initiate Phase 2 Trial of Ok-101 in Neuropathic Corneal Pain

OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer, Effective September 1, 2023

New minor risk - Shareholder dilution

OKYO Pharma Limited Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular Ok-101 for Dry Eye Disease

OKYO Pharma's Ordinary Shares of No Par Value, Fully Paid Cancels from Admission to Trading on London Stock Exchange

OKYO Pharma Announces Change of Delisting Date to 22 May 2023

OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease

OKYO Pharma Limited Announces U.S. IND Filing on Ok-101 for the Treatment of Dry Eye Disease

OKYO Pharma Plans Fourth Quarter 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm

OKYO Pharma Limited, Annual General Meeting, Sep 07, 2022

OKYO Pharma Limited announced delayed 20-F filing

OKYO Pharma Limited Announces Successful Completion of A Pre-IND Meeting with the U.S. Food and Drug Administration on the Development of OK-101 to Treat Dry Eye Disease

OKYO Pharma Limited Announces First-in-Class Drug Candidate OK-101 Displaying Both Anti-inflammatory and Ocular Pain-Reducing Potential to Treat Dry Eye Disease

OKYO Pharma Announces Positive Data and Results in an Animal Model Using Topically Administered OK-201 to Treat Neuropathic Ocular Pain

OKYO Pharma Limited Has U.S. Patent Issues Covering its Lipid Conjugated Peptide Analogues for Treating Ocular Pain and Inflammation

Okyo Pharma Limited Announces Filing of A Patent Application Covering the Use of Chemerin and Associated Analogues to Treat “Cytokine Storm” Associated with COVID-19 and ARDS

OKYO Pharma Limited Appoints Gary S. Jacob as Chief Executive Officer

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin